Trial Profile

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibezapolstat (Primary) ; Vancomycin
Indications Clostridium difficile infections
Focus Adverse reactions; Therapeutic Use
Sponsors Acurx Pharmaceuticals

Most Recent Events

24 Feb 2025 Results presented in the Acurx Pharmaceuticals Media Release.
06 Jan 2025 Results presented in the Acurx Pharmaceuticals Media Release.
18 Nov 2024 According to an Acurx Pharmaceuticals media release, results from this study presented at the Inaugural Peggy Lillis Foundation (virtual) Scientific Symposium, held on Friday, November 15, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com